BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 25693420)

  • 21. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
    He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
    PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
    Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA
    Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
    Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
    Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
    Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
    J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron tomographic assessment of androgen receptors in prostatic carcinoma.
    Dehdashti F; Picus J; Michalski JM; Dence CS; Siegel BA; Katzenellenbogen JA; Welch MJ
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):344-50. PubMed ID: 15726353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.
    Mortimer JE; Dehdashti F; Siegel BA; Trinkaus K; Katzenellenbogen JA; Welch MJ
    J Clin Oncol; 2001 Jun; 19(11):2797-803. PubMed ID: 11387350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
    Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
    Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[
    Katzenellenbogen JA
    Nucl Med Biol; 2021 Jan; 92():24-37. PubMed ID: 32229068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Women's Health Update: Growing Role of PET for Patients with Breast Cancer.
    Ulaner GA; Vaz SC
    Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
    Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
    Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Application of 18 F-FES PET in Clinical Cancer Care : A Systematic Review.
    Huang YT; Chen TW; Chen LY; Huang YY; Lu YS
    Clin Nucl Med; 2023 Sep; 48(9):785-795. PubMed ID: 37482660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.
    Evangelista L; Guarneri V; Conte PF
    Curr Radiopharm; 2016; 9(3):244-257. PubMed ID: 27774910
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
    Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
    Peterson LM; Kurland BF; Schubert EK; Link JM; Gadi VK; Specht JM; Eary JF; Porter P; Shankar LK; Mankoff DA; Linden HM
    Mol Imaging Biol; 2014 Jun; 16(3):431-40. PubMed ID: 24170452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.
    Fox JJ; Gavane SC; Blanc-Autran E; Nehmeh S; Gönen M; Beattie B; Vargas HA; Schöder H; Humm JL; Fine SW; Lewis JS; Solomon SB; Osborne JR; Veach D; Sawyers CL; Weber WA; Scher HI; Morris MJ; Larson SM
    JAMA Oncol; 2018 Feb; 4(2):217-224. PubMed ID: 29121144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
    Peterson LM; Mankoff DA; Lawton T; Yagle K; Schubert EK; Stekhova S; Gown A; Link JM; Tewson T; Krohn KA
    J Nucl Med; 2008 Mar; 49(3):367-74. PubMed ID: 18287268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Report on the PET/CT Image-Based Radiation Dosimetry of [
    McCall KC; Liu M; Cheng SC; Abbott A; Dubey S; Young D; Johnston M; Van den Abbeele AD; Overmoyer B; Jacene H
    J Nucl Med Technol; 2023 Sep; 51(3):204-210. PubMed ID: 37316304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.